tbuckley/cabot-search huggingface dataset:
Single-agent platelet-derived growth factor (PDGF) receptor inhibitor therapy for castration-resistant prostate cancer with bone metastases
Authors: P. Mathew, L. C. Pagliaro, N. M. Tannir, S. Tu, V. Marcott, L. Patterson, K. Reed, N. Bekele, C. J. Logothetis
Journal: Journal of Clinical Oncology (2008)

5164 Background: Phosphorylated PDGF receptor (PDGFR) is frequently expressed in bone metastases from prostate cancer and pre-clinical models have implicated autocrine and paracrine signaling by PDGF in progression of prostate cancer in bone. Tandutinib possesses potent in-vitro inhibitory activity toward PDGFR-β, the dominant receptor isoform expressed in bone metastases (BM) from prostate cancer. To formally assess the effects of a chronically-administered highly-potent PDGFR inhibitor in this disease state, a Phase II study of tandutinib was conducted. Methods: Men with progressive castration-resistant prostate cancer (CRPC) with BM and prior front-line taxane therapy were treated with oral tandutinib 500mg twice daily under a two-stage design with the 8 week freedom-from-progression (FFP) rate as the primary endpoint. If > 3 patients of 15 were progression-free at 56 days, an additional 15 patients were to be accrued. If > 7/30 patients were progression-free at 56 days, the drug would be declared worthy of further study. The trial was designed to have 87% power to reject a null FFP rate of 10% when the true rate was 33% (Type I error rate=0.02). Secondary endpoints included prostate-specific antigen and bone marker kinetics, objective responses and toxicity outcomes. Results: Among 18 patients registered (ages 47–81, median 66 years), 15 were evaluable for efficacy. Two patients with taxane-resistant CRPC (13%) were free from symptomatic or radiological progression beyond 8 weeks (35, 50 weeks), with PSA-declines of 50% and 40% respectively. Fifteen patients experienced progression and 1 patient discontinued therapy for toxicity within 8 weeks. Measurable disease in 1/15 patients progressed after 8 weeks. No PSA-declines were noted with drug discontinuation. Seven (39%) patients required dose-reductions for grade 2–3 nausea, vomiting or diarrhea. Fatigue (grade 2–3, n=10) was the most common toxicity. Urine N-telopeptide and serum bone-specific alkaline phosphatase declined in 40% and 33% of patients respectively. Conclusions: A small fraction of taxane-resistant CRPC with BM experience PSA-declines and freedom-from-progression up to 50 weeks with single-agent PDGFR inhibitor therapy. Supported by NCI-CTEP. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Bayer, Bristol- Myers Squibb, Onyx Bayer, Onyx, Pfizer
Differentiation Induction of Mouse Neural Stem Cells in Hydrogel Tubular Microenvironments with Controlled Tube Dimensions
Authors: Hiroaki Onoe, Midori Kato‐Negishi, Akane Itou, Shoji Takeuchi
Journal: Advanced Healthcare Materials (2016)

In this paper, a tubular 3D microenvironment created in a calcium alginate hydrogel microtube with respect to the effect of scaffold dimensions on the differentiation of mouse neuronal stem cells (mNSCs) is evaluated. Five types of hydrogel microtubes with different core diameters (≈65–200 μm) and shell thicknesses (≈30–110 μm) are fabricated by using a double coaxial microfluidic device, and differentiation of encapsulated mNSCs is induced by changing the growth medium to the differentiation medium. The influence of the microtube geometries is examined by using quantitative real‐time polymerase chain reaction and fluorescent immunocytochemistry. The analyses reveal that differences in microtube thickness within 30–110 μm affected the relative Tuj1 expression but do not affect the morphology of encapsulated mNSCs. The diameters of cores influence both the relative Tuj1 expression and morphology of the differentiated neurons. It is found that the tubular microenvironment with a core diameter of less than ≈100 μm contributes to forming highly viable and aligned neural tissue. The tubular microenvironment can provide an effective method for constructing microfiber‐shaped neural tissues with geometrically controlled differentiation induction.
Preliminary Azd9291 Western and Asian Clinical Pharmacokinetics (Pk) in Patients (Pts) and Healthy Volunteers (Hv): Implications for Formulation, Dose and Dosing Frequency in Pivotal Clinical Studies
Authors: D. Planchard, P.A. Dickinson, K.H. Brown, D. Kim, S. Kim, Y. Ohe, E. Felip, P. Leese, M. Cantarini, M. Ranson
Journal: Annals of Oncology (2014)
Uninsured utilization of the mobile mammography: 10-year analysis.
Authors: Elizabeth Carloss Riley, Shesh Rai, Jainmin Pan, Lane Roland, Laura Barkley, Sarah Mizuguchi
Journal: Journal of Clinical Oncology (2014)

12 Background: Mobile Mammography Units (MMU) historically increase access breast cancer screening to uninsured patients. Our group previously reported insurance status predicts MMU repeat utilization (insured cohort most likely to repeat.) The purpose of this study is to examine the uninsured subset in multivariable analysis to understand the low repeat utilization by this group. Methods: From Jan 2001 to Dec 2010, 48,324 screening mammograms were performed in the largest county in KY. Of 21,587 unique subjects, 9,422 were uninsured (44%.) Demographic data was retrospectively reviewed to identify age, race/ethnicity, insurance status and location for each encounter. Utilization was defined as once or more than two times in a 10-year period. P-values were calculated using Chi-square test for comparison between the two groups. Odds ratio and its 95% confidence interval were provided. Logistics regression analysis is used to jointly model the effect of independent factors on repeat unitization of MMU. Results were declared significant at significance level of 5%. Results: Race, location, and age remain independent variables in likelihood of repeat utilization within a 10-year period (p value &lt; .001.) The estimated OR are depicted in the table. We previously reported in the entire dataset (all insurance cohorts) and estimated OR of Whites (W) vs Blacks (B) of 0.897 (CI 0.843-0.955) and Hispanics (H) vs B 0.701 (CI 0.604-0.813.) Conclusions: Within the uninsured cohort, race and location remain independent predictors of repeat utilization of the MMU. However, the significance is weaker between W and B (p &lt; .004 versus &lt; .001) in the uninsured group than in the entire dataset which may suggest that insurance type becomes a stronger predictor of repeat utilization than race although further analysis will be necessary to confirm this trend.[Table: see text]
In patients with SBP ≥ 130 mm Hg and CV risk, intensive vs standard BP control reduced CV events and mortality
Authors: Saurav Chatterjee, Partha Sardar, Anasua Chakraborty, Sanjay Chatterjee
Journal: Annals of Internal Medicine (2016)

ACP Journal Club16 February 2016In patients with SBP ≥ 130 mm Hg and CV risk, intensive vs standard BP control reduced CV events and mortalitySaurav Chatterjee, MD, Partha Sardar, MD, Anasua Chakraborty, MD, Sanjay Chatterjee, MDSaurav Chatterjee, MDMount Sinai St. Luke's-Roosevelt Hospitals, New York, New York, USA (S.C.)Search for more papers by this author, Partha Sardar, MDUniversity of Utah Health Sciences Center, Salt Lake City, Utah, USA (P.S.)Search for more papers by this author, Anasua Chakraborty, MDThomas Jefferson University Hospitals, Philadelphia, Pennsylvania, USA (A.C.)Search for more papers by this author, Sanjay Chatterjee, MDApollo Gleneagles Hospital, Kolkata, India (S.C.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2016-164-4-015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationSPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103-16. https://pubmed.ncbi.nlm.nih.gov/26551272Clinical Impact RatingsGIM/FP/GP: Cardiology: Reference1 ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85. [PMID: 20228401] Google Scholar Author, Article, and Disclosure InformationAuthors: Saurav Chatterjee, MD; Partha Sardar, MD; Anasua Chakraborty, MD; Sanjay Chatterjee, MDAffiliations: Mount Sinai St. Luke's-Roosevelt Hospitals, New York, New York, USA (S.C.)University of Utah Health Sciences Center, Salt Lake City, Utah, USA (P.S.)Thomas Jefferson University Hospitals, Philadelphia, Pennsylvania, USA (A.C.)Apollo Gleneagles Hospital, Kolkata, India (S.C.)This article was published at Annals.org on 2 February 2016. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoReview: More- vs less-intensive BP-lowering regimens reduce major CV events Saurav Chatterjee , Partha Sardar , Anasua Chakraborty , Sanjay Chatterjee Metrics 16 February 2016Volume 164, Issue 4Page: JC15KeywordsBlood pressureCardiovascular disease riskEstimated glomerular filtration rateHazard ratioHeart failureHypotensionMortalityMyocardial infarctionStrokeSystolic pressure ePublished: 16 February 2016 Issue Published: 16 February 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission.
Authors: H. J. Gray, A. A. Secord, M. L. Anderson, G. DelPriore, N. E. Tchabo, J. S. Berek
Journal: Journal of Clinical Oncology (2010)

TPS171 Background: MUC-1 is a highly immunogenic antigen that is widely expressed in epithelial ovarian carcinoma (EOC) making it an ideal target for vaccine therapy. Prior phase I and II studies conducted in Australia of the MUC-1 dendritic cell vaccine (CVac) in heavily pretreated, advanced disease patients showed minimal toxicities and prolonged disease stabilization. The purpose of this trial is to determine the safety and efficacy of a MUC-1 dendritic cell vaccine (CVac) in ovarian cancer patients who are in clinical remission after first or second-line therapy. Methods: Women with stage III or IV ovarian, fallopian tube, or primary peritoneal carcinoma who have had a complete response (CR) based on clinical and radiologic studies after first or second-line chemotherapy will be eligible for this study. Planned sample size is 60 patients. The first 6 patients will be treated with CVac open-label to ensure consistency of manufacturing. The next 54 patients will be randomized 1:1 to CVac or standard of care (observation). Patients receiving vaccine will undergo leukopheresis followed by in vitro loading of dendritic cells with MUC-1. They will receive a total of 10 intradermal vaccine administrations over 52 weeks (every 4 weeks × 7, then every 8 weeks × 3). Clinical assessments will be every 4 weeks and radiologic assessments will be every 12 weeks. Primary endpoints are the safety of CVac in this population and effect on progression-free survival (PFS). Secondary endpoints are effect on overall survival (OS) and immunologic parameters, including MUC-1 antibodies and intracelluar cytokine assays. No significant financial relationships to disclose.
Cancer of the Breast
Authors: Joseph C. Bloodgood
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical trials financial compliance: The Principal Investigators and liability
Authors: K. Willenberg
Journal: Journal of Clinical Oncology (2004)

6097 Background: Clinical trials compliance has become more scrutinized with the national coverage decision and billable services. Meticulous financial planning is essential to fiscal success. Cost effective achievement through billing and accounts receivable will ensure compliance with federal guidelines. A clinical trials office conducting audits of patients” bills minimizes problems in billing compliance. Methods: A large clinical trials office manually reviewed HCFA Uniform Bill-92 for accuracy in charging. A conscientious effort was made to properly identify protocol specific research procedures and tests and budgets were established with accuracy. Standard of care, routine tests were acknowledged and an effort was made to code properly. “Research only” tests and procedures were placed on proper account as a new encounter form was established within the Cancer Clinic. In-services were executed to advise staff of agreed upon budget. Patients' bills were reconciled against schedule of events calendars and study milestones by nurse and administrative assistant. Accuracy in HCFA Uniform Bill charges increased by 50%. Results: Patients and third party payers were not billed inappropriately for research related activities. Patients bills were hand tracked when they had certain types of third party payers to ensure billing compliance. Sponsored research was appropriately and accurately contracted to cover research related activities. Financial and research compliance have become a priority for the University with new positions created to continue to work on processes for the future. Conclusions: Clinical research priorities include billing process improvement, compliance monitoring, and clinical trials management. Training and educational opportunities for precision budgeting are being initiated with the goal of offering a standardized budget formatting tool within the next few months. A review process by a specialized clinical trials budget expert has begun to assess financial feasibility and risk, as well as tracking billing compliance. No significant financial relationships to disclose.
The biological impact of e-cigarettes on airway epithelial cell transformation and gene expression
Authors: Stacy J. Park, Tonya C. Walser, Linh M. Tran, Catalina Perdomo, Teresa Wang, Long-Sheng Hong, Paul Pagano, Rui Li, Zhe Jing, Elvira Liclican, Jill E. Larsen, Kostyantyn Krysan, Michael C. Fishbein, John D. Minna, Marc E. Lenburg, Avrum Spira, Steven M. Dubinett
Journal: Journal of Thoracic Oncology (2016)
Synchronous and metachronous malignant tumors.
Authors: I. Mehdi
Journal: Journal of Clinical Oncology (2010)

e19664 Background: The incidence of second primary synchronous or metachronous tumor is increasing and reported as high as 10%. Meta analyses show the frequency of second primary tumor (SPT) as 3-5%, a third primary tumor (TT) as 0.5%, and a fourth primary tumor (QT) as 0.3%. Persistent carcinogenic influence, genetic instability, field cancerization, increasing use of systemic chemotherapy or radiotherapy, hormonal manipulation, targeted therapy, genetic manipulation, immune suppression, tissue transplantation, and improved survival are all implicated. Methods: All diagnosed first primary tumor that experienced a subsequent tumor, at AOI Sabratha Libya from Feb 2003 to August 2009 are included. The cases were analyzed for morphology and histology of 1st primary tumor, age and gender, treatment received for the first tumor, time interval elapsed between these tumors, morphology and histology of second tumor, and the treatment conferred for the second primary tumor. Results: The number of cases with synchronous and metachronous tumors were 41 out of total 4,025 (1.02%). There were 16 males and 25 female (M:F 1:1.6). The age range was 16-75 years, with median age as 43 years. The follow up time was 24-150 months. The minimum time to have a second primary tumor was 2 months, while the maximum interval between the two tumors was eleven years. The first primary tumors were breast, ovary, GIT and urinary bladder. The patients received surgery, radiotherapy, chemotherapy, and hormonal therapy alone or as multi-modality treatment. The most frequent subsequent synchronous or metachronous tumors were breast, ovary and gastrointestinal tumors. Conclusions: It is imperative that patients with a primary malignant tumor should be thoroughly, closely, and regularly be followed at regular intervals. Genetic counseling, risk estimation, and cancer screening must be emphasized. Every subsequent occurring tumor must be biopsied. Chemoprevention strategies must be instituted when available and feasible. The effect of 1st tumor on the 2nd primary or vice versa are still not fully understood and need to be explored. The 2nd primary tumor is usually more aggressive, more treatment resistant, and metastasizes early, requiring a more aggressive treatment strategy. No significant financial relationships to disclose.
Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study
Authors: Sydney Dubois, Pierre-Julien Viailly, Sylvain Mareschal, Elodie Bohers, Philippe Bertrand, Philippe Ruminy, Catherine Maingonnat, Jean-Philippe Jais, Pauline Peyrouze, Martin Figeac, Thierry J. Molina, Fabienne Desmots, Thierry Fest, Corinne Haioun, Thierry Lamy, Christiane Copie-Bergman, Josette Brière, Tony Petrella, Danielle Canioni, Bettina Fabiani, Bertrand Coiffier, Richard Delarue, Frédéric Peyrade, André Bosly, Marc André, Nicolas Ketterer, Gilles Salles, Hervé Tilly, Karen Leroy, Fabrice Jardin
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Next-generation sequencing (NGS) has detailed the genomic characterization of diffuse large B-cell lymphoma (DLBCL) by identifying recurrent somatic mutations. We set out to design a clinically feasible NGS panel focusing on genes whose mutations hold potential therapeutic impact. Furthermore, for the first time, we evaluated the prognostic value of these mutations in prospective clinical trials. Experimental Design: A Lymphopanel was designed to identify mutations in 34 genes, selected according to literature and a whole exome sequencing study of relapsed/refractory DLBCL patients. The tumor DNA of 215 patients with CD20+de novo DLBCL in the prospective, multicenter, and randomized LNH-03B LYSA clinical trials was sequenced to deep, uniform coverage with the Lymphopanel. Cell-of-origin molecular classification was obtained through gene expression profiling with HGU133+2.0 Affymetrix GeneChip arrays. Results: The Lymphopanel was informative for 96% of patients. A clear depiction of DLBCL subtype molecular heterogeneity was uncovered with the Lymphopanel, confirming that activated B-cell–like (ABC), germinal center B-cell like (GCB), and primary mediastinal B-cell lymphoma (PMBL) are frequently affected by mutations in NF-κB, epigenetic, and JAK–STAT pathways, respectively. Novel truncating immunity pathway, ITPKB, MFHAS1, and XPO1 mutations were identified as highly enriched in PMBL. Notably, TNFAIP3 and GNA13 mutations in ABC patients treated with R-CHOP were associated with significantly less favorable prognoses. Conclusions: This study demonstrates the contribution of NGS with a consensus gene panel to personalized therapy in DLBCL, highlighting the molecular heterogeneity of subtypes and identifying somatic mutations with therapeutic and prognostic impact. Clin Cancer Res; 22(12); 2919–28. ©2016 AACR. See related commentary by Lim and Elenitoba-Johnson, p. 2829
Treatment of early breast cancer (EBC): A long-term follow-up study—GOCS experience
Authors: J. Iturbe, A. Zwenger, J. A. Lacava, P. Perez Verdera, C. Vallejo, A. Romero, J. P. Leone, J. Perez, M. Maccihavelli, B. Leone
Journal: Journal of Clinical Oncology (2009)

e11610 Background: Most cases of breast cancer are diagnosed at early stage of disease, therefore treatment is oriented to increase the relapse-free survival (RFS) and overall survival (OS). The prognosis, in comparison to other malignancies, has improved in the last decades as a result of mammographic screening. The objective of this study was to evaluate the incidence of local and distant recurrence, RFS and OS in women with EBC. Methods: From 01/1978 to 12/2004, 929 women with EBC were identified, 350 were stage I and 579 stage II (AJCC 2002). RFS was analyzed from the date of initial diagnosis to the date of local or distant recurrence. OS was estimated from the date of initial diagnosis to the last follow-up or date of death. Multivariate regression analyses were carried out using proportional hazard model proposed by Cox. RFS and OS were evaluated by the product-limit method of Kaplan and Meier, and differences between curves were assessed by means of log-rank test. Results: Median age was 51 years (28–92). Conservative surgery was performed in 69.7% of patients (pts). The median number of nodes examined was 17. Hormone receptors were ER+ in 65% and PR+ in 62% of pts. Adjuvant radiation therapy was administered to 73% of pts, whereas adjuvant chemotherapy to 29% and adjuvant hormone therapy to 18.5% of cases. Combined chemotherapy and hormone therapy was given to 34% of women. The median follow-up was 8.4 years (0.3–30). Local recurrence was documented in 37 pts (3.8%) whereas 269 developed metastatic disease (29%). Bilateral breast cancer was seen in 102 cases (10.9%) and 91 pts (9.7%) developed 2nd malignancies. RFS rate at 5, 10, 15, 20 and 25 years was 71%, 67%, 65%, 65% and 64% respectively. OS at 5, 10, 15, 20 and 25 years was 82%, 62%, 49%, 39% and 28% respectively. Factors that had an effect in OS demonstrated by the multivariate regression analysis were: histologic grade, tumor size, ER status, vascular and nodal involvement (p &lt; 0.001). Conclusions: Clinical outcomes in EBC in our experience are similar to that reported in international literature. This group of pts continues to have a good prognosis as shown by the OS rate at 5, 10, 15, 20 and 25 years, although high percentage of pts continue to have recurrence and die from breast cancer after 5, 10, 15, 20 and 25 years of follow-up. No significant financial relationships to disclose.